# A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration

> **NCT07718165** · PHASE1 · RECRUITING · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 247 (estimated)

## Conditions studied

- Solid Tumor (Phase I)

## Interventions

- **DRUG:** ABSK211

## Key facts

- **NCT ID:** NCT07718165
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-28
- **Primary completion:** 2029-12-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 247 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07718165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07718165, "A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07718165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*